Cargando…

Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients

SIMPLE SUMMARY: The availability of multiple gene panel testing allows us to identify germline pathogenic variants of validated cancer genes. We evaluated the prevalence and clinical/prognostic impact of deleterious germline mutations in OC patients. Germline panel testing should be performed for al...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imterat, Majdi, Harter, Philipp, Rhiem, Kerstin, Heitz, Florian, Schneider, Stephanie, Concin, Nicole, Moubarak, Malak, Welz, Julia, Vrentas, Vasileios, Traut, Alexander, Hahnen, Eric, Schmutzler, Rita, du Bois, Andreas, Ataseven, Beyhan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177155/ https://www.ncbi.nlm.nih.gov/pubmed/37174000 http://dx.doi.org/10.3390/cancers15092534

Ejemplares similares

Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer
por: Heitz, Florian, et al.
Publicado: (2023)

Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience
por: Moubarak, Malak, et al.
Publicado: (2022)

Prevalence of BRCA1 and BRCA2 Mutations in Patients with Primary Ovarian Cancer – Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?
por: Ataseven, Beyhan, et al.
Publicado: (2020)

Pathogenic germline variants in SMARCA4 and further cancer predisposition genes in early onset ovarian cancer
por: Herold, Natalie, et al.
Publicado: (2023)

Response to the letter of Fagotti et al. regarding the manuscript: “Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery”
por: Heitz, Florian, et al.
Publicado: (2016)

Early-stage epithelial ovarian cancer: is systematic lymph node staging mandatory?
por: Imterat, Majdi, et al.
Publicado: (2021)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

Non-small cell neuroendocrine carcinoma of the ovary in a BRCA2-germline mutation carrier: A case report and brief review of the literature
por: Herold, Natalie, et al.
Publicado: (2018)

Satisfaction and Quality of Life of Healthy and Unilateral Diseased BRCA1/2 Pathogenic Variant Carriers after Risk-Reducing Mastectomy and Reconstruction Using the BREAST-Q Questionnaire
por: Herold, Natalie, et al.
Publicado: (2022)

Dataset on patients with Recurrent Borderline Ovarian Tumors and Table with Review of Literature on Fertility and Oncologic Outcomes of patients with Borderline Ovarian Tumors
por: Plett, Helmut, et al.
Publicado: (2020)

Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)
por: Harter, Philipp, et al.
Publicado: (2017)

Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia‐like phenotype, and no chromosome fragility
por: Keupp, Katharina, et al.
Publicado: (2019)

Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer—Impact for Diagnosis and Treatment Monitoring
por: Braicu, Elena Ioana, et al.
Publicado: (2021)

Long-term survival of a BRCA2 mutation carrier following second ovarian cancer relapse using PARPi therapy: A case report
por: Bredow, Kathrin, et al.
Publicado: (2022)

Prevalence of Pathogenic Germline Variants in Women with Non-Familial Unilateral Triple-Negative Breast Cancer
por: Rhiem, Kerstin, et al.
Publicado: (2023)

Rare deleterious germline variants and risk of lung cancer
por: Liu, Yanhong, et al.
Publicado: (2021)

Prevalence of deleterious ATM germline mutations in gastric cancer patients
por: Huang, Dong-Sheng, et al.
Publicado: (2015)

Analysis of 30 Putative BRCA1 Splicing Mutations in Hereditary Breast and Ovarian Cancer Families Identifies Exonic Splice Site Mutations That Escape In Silico Prediction
por: Wappenschmidt, Barbara, et al.
Publicado: (2012)

Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC)
por: Fotopoulou, Christina, et al.
Publicado: (2021)

Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer
por: de Voer, Richarda M., et al.
Publicado: (2015)

Deleterious effects of endocrine disruptors are corrected in the mammalian germline by epigenome reprogramming
por: Iqbal, Khursheed, et al.
Publicado: (2015)

Mitochondrial fragmentation drives selective removal of deleterious mtDNA in the germline
por: Lieber, Toby, et al.
Publicado: (2019)

Prevalence of Cancer Predisposition Germline Variants in Male Breast Cancer Patients: Results of the German Consortium for Hereditary Breast and Ovarian Cancer
por: Rolfes, Muriel, et al.
Publicado: (2022)

RAD51C deletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families
por: Schnurbein, Gioia, et al.
Publicado: (2013)

Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer
por: Heitz, Florian, et al.
Publicado: (2022)

“You Always Have It in the Back of Your Mind”—Feelings, Coping, and Support Needs of Women with Pathogenic Variants in Moderate-Risk Genes for Hereditary Breast Cancer Attending Genetic Counseling in Germany: A Qualitative Interview Study
por: Stracke, Claudia, et al.
Publicado: (2022)

Systemic mastocytosis, in the context of a deleterious germline SDHC variant, treated with ripretinib
por: Saheb Kashaf, Sara, et al.
Publicado: (2023)

Decision Aids for Preventive Treatment Alternatives for BRCA1/2 Mutation Carriers: a Systematic Review
por: Krassuski, Lisa Marlene, et al.
Publicado: (2021)

Psychological factors and the uptake of preventative measures in BRCA1/2 pathogenic variant carriers: results of a prospective cohort study
por: Dick, Julia, et al.
Publicado: (2022)

Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany
por: Reinisch, Mattea, et al.
Publicado: (2023)

Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer
por: Weber-Lassalle, Nana, et al.
Publicado: (2019)

Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history
por: Engel, Christoph, et al.
Publicado: (2018)

Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice
por: Bruzas, Simona, et al.
Publicado: (2021)

Evaluation of two evidence-based decision aids for female BRCA1/2 mutation carriers in Germany: study protocol for a randomised controlled parallel-group trial
por: Kautz-Freimuth, Sibylle, et al.
Publicado: (2022)

A deleterious RNF43 germline mutation in a severely affected serrated polyposis kindred
por: Taupin, Douglas, et al.
Publicado: (2015)

Germline rare deleterious variant load alters cancer risk, age of onset and tumor characteristics
por: Esai Selvan, Myvizhi, et al.
Publicado: (2023)

Precursor fractions of neurotensin and enkephalin might point to molecular mechanisms of cancer risk modulation during a lifestyle-intervention in germline BRCA1/2 gene mutation carriers
por: Grill, Sabine, et al.
Publicado: (2021)

Performance of In Silico Prediction Tools for the Detection of Germline Copy Number Variations in Cancer Predisposition Genes in 4208 Female Index Patients with Familial Breast and Ovarian Cancer
por: Lepkes, Louisa, et al.
Publicado: (2021)

Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in BRCA1/2: results of the observational AGO-TR1 study (NCT02222883)
por: Hauke, Jan, et al.
Publicado: (2022)

Effectiveness of evidence-based decision aids for women with pathogenic BRCA1 or BRCA2 variants in the german health care context: results from a randomized controlled trial
por: Kautz-Freimuth, Sibylle, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ivec0d5s0tabgfqhotant8ns2s